Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
25 studies found for:    "Hemophagocytic lymphohistiocytosis"
Show Display Options
Download search resultsDownload the search results for:
"Hemophagocytic lymphohistiocytosis" (25 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit;   Drug: Etoposide;   Drug: Intrathecal Methotrexate;   Drug: hydrocortisone
2 Recruiting Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
Condition: Hemophagocytic Lymphohistiocytosis (HLH)
Intervention: Drug: tocilizumab
3 Recruiting Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: IST and/or alloHCT
4 Unknown  Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Conditions: Chediak-Higashi Syndrome;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: filgrastim;   Drug: methotrexate;   Procedure: allogeneic hematopoietic stem cell transplantation
5 Not yet recruiting Reduced Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (PIDs) (BMT Clinical Trials Network 1204)
Conditions: Hemophagocytic Lymphohistiocytosis;   CAEBV;   Chronic Granulomatous Disease;   HIGM-1;   Leukocyte Adhesion Deficiency;   IPEX
Intervention: Biological: Hematopoietic Stem Cell Transplant
6 Recruiting Administration of Donor T Cells With the Caspase-9 Suicide Gene
Conditions: Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Non Hodgkin Lymphoma;   Hemophagocytic Lymphohistiocytosis;   Familial Hemophagocytic Lymphohistiocytosis;   Hemophagocytic Syndrome;   Epstein Barr Virus Infection;   X-linked Lymphoproliferative Disease
Interventions: Biological: iCaspase9-transduced T cells;   Drug: AP1903
7 Recruiting T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Conditions: Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
Interventions: Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
8 Active, not recruiting Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: Dexamethasone;   Drug: Etoposide;   Drug: Cyclosporin;   Procedure: Intrathecal therapy;   Procedure: Stem cell transplant
9 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation
10 Recruiting A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis in Whom the Disease Has Reactivated or an Unsatisfactory Response Has Been Achieved
Condition: Primary Hemophagocytic Lymphohistiocytosis
Intervention: Biological: NI-0501
11 Recruiting Trial of DA-EPOCH Regimen for NHL With HLH
Condition: NHL With Hemophagocytic Lymphohistiocytosis
Intervention: Drug: DA-EPOCH
12 Recruiting Children and Adult Hemophagocytic Syndrome (HLHa)
Condition: Hemophagocytic Syndrome
Intervention: Biological: Identification of biological markers
13 Recruiting Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: NI-0501
14 Unknown  Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
Condition: Nonneoplastic Condition
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: dexamethasone;   Drug: etoposide;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: therapeutic hydrocortisone;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
15 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
16 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
17 Active, not recruiting
Has Results
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
Interventions: Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
18 Not yet recruiting Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Conditions: Primary Immune Deficiency Disorders;   Hemophagocytic Lymphohistiocytosis;   Inherited Bone Marrow Failure Syndrome;   Hemoglobinopathies;   Metabolic Disorders
Intervention: Biological: BPX-501 and AP1903
19 Recruiting Abatacept Reduced Intensity for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
Interventions: Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
20 Active, not recruiting Stem Cell Transplant for Immunologic or Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
Interventions: Procedure: Stem Cell Transplant;   Drug: Fludarabine, melphalan, ATG or Campath

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years